The role of IL-15 in challenging Acquired Immunodeficiency Syndrome

Cytokine

Volumn 57, Issue 1, 2012, Pages 54-60

  D'Ettorre, Gabriella ^a   Andreotti, Mauro ^b   Ceccarelli, Giancarlo ^a   Galluzzo, Clementina Maria ^b   Mallano, Alessandra ^b   Massetti, Anna Paola ^a   Tierno, Francesca ^a   Stella, Stefano ^a   Amici, Roberta ^b   Vella, Stefano ^b   Mastroianni, Claudio M ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Department of Therapeutic Research and Medicines Evaluation ^*  (Italy)

Author keywords

HIV 1 infection; IL 12; IL 15; IL 2; NK cells

Indexed keywords

ANTIGEN P24; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD3+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; HIV CORE PROTEIN P24; HIV-1; HUMANS; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84155163893     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.09.026     Document Type: Article

References (52)

1. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
2. Markowitz M., Vesanen M., Tenner-Racz K., Cao Y., Binley J.M., Talal A., et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999, 179:527-537.
3. Mitsuyasu D. Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients. J Infect Dis 2002, 185:S115-S122.
4. Johnsons W.E., Desroseirs R.C. Viral persistence. HIV's strategies of immune system evasion. Ann Rev Med 2002, 53:499-518.
5. Montoya C.J., Rugeles M.T., Landay A.L. Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy. Expert Rev Anti Infect Ther 2006, 4:767-780.
6. Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., Caligiuri M.A. NK cells and DC interactions. Trends Immunol 2004, 25:47-52.
7. Degli-Esposti M.A., Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005, 5:112-124.
8. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002, 2:957-964.
9. Alter G., Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009, 265:29-42.
10. Lifson J.D., Nowak M.A., Goldstein S., Rossio J.L., Kinter A., Vasquez G., et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997, 71:9508-9514.
11. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
12. Medzhitov R., Janeway C. Innate immunity. N Engl J Med 2000, 343:338-344.
13. Levy J.A., Scott I., Mackewicz C. Protection from HIV/AIDS: the importance of innate immunity. Clin Immunol 2003, 108:167-174.
14. Birol C.A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol 1999, 2:374-381.
15. Prlic M., Blazar B.R., Farrar M.A., Jameson S.C. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003, 197:967-976.
16. Berard M., Brandt K., Bulfone-Paus S., Tough D.F. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol 2003, 170:5018-5026.
17. Zhang X., Sun S., Hwang I., Tough D.F., Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998, 8:591-599.
18. Mueller Y.M., Katsikis P.D. IL-15 in HIV infection: pathogenic or therapeutic potential?. Eur Cytokine Netw 2010, 21:219-221.
19. Nagler A., Lanier L.L., Cwirla S., Phillips J.H. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989, 143:3183-3191.
20. Rodriguez A.R., Arulanandam B.P., Hodara V.L., McClure H.M., Cobb E.K., Salas M.T., et al. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees. J Gen Virol 2007, 88:641-651.
21. Fehniger T.A., Herbein G., Yu H., Para M.I., Bernstein Z.P., O'Brien W.A., et al. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998, 161:6433-6438.
22. Germeraad W.T., Asami N., Fujimoto S., Mazda O., Katsura Y. Efficient retrovirus-mediated gene transduction into murine hematopoietic stem cells and long-lasting expression using a Transwell coculture system. Blood 1994, 84:780-788.
23. Nicastri E., Palmisano L., Sarmati L., D'Ettorre G., Parisi S.G., Andreotti M., et al. HIV-1 Residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens. Curr HIV Res. 2008, 6:261-266.
24. Lewin S.R., Evans V.A., Elliott J.H., Spire B., Chomont N. Finding a cure for HIV: will it ever be achievable?. J Int AIDS Soc. 2011, 14:4.
25. Haggerty C.M., Pitt E., Siliciano R.F. The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Curr Opin HIV AIDS 2006, 1:62-68.
26. Yang H.C. Primary cell models of HIV latency. Curr Opin HIV AIDS 2011, 6:62-67.
27. Chomont N., Dafonseca S., Vandergeeten C., Ancuta P., Sékaly R.P. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS 2011, 6:30-36.
28. Brooks D.G., Kitchen S.G., Kitchen C.M., Scripture-Adams D.D., Zack J.A. Generation of HIV latency during thymopoiesis. Nat Med 2001, 7:459-464.
29. Brenchley J.M., Douek D.C. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 2008, 3:356-361.
30. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007, 4:10-15.
31. Ahmed N., Heslop H.E., Mackall C.L. T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am 2010, 57:83-96.
32. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
33. Biron C.A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr Opin Microbiol 1999, 2:374-381.
34. French A.R., Sjölin H., Kim S., Koka R., Yang L., Young D.A., et al. DAP12 signaling directly augments proliferative cytokine stimulation of NK cells during viral infections. J Immunol. 2006, 177:4981-4990.
35. + T cells is dispensable for T cell memory. Proc Natl Acad Sci USA 2003, 100:4724-4729.
36. Huntington N.D., Puthalakath H., Gunn P., Naik E., Michalak E.M., Smyth M.J., et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol 2007, 8:856-863.
37. Koka R., Burkett P.R., Chien M., Chai S., Chan F., Lodolce J.P., et al. Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice. J Exp Med 2003, 197:977-984.
38. Ma A., Koka R., Burkett P.R. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24:657-679.
39. Prlic M., Blazar B.R., Farrar M.A., Jameson S.C. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003, 197:967-976.
40. + bone marrow-derived cells. Blood 2004, 103:988-994.
41. + T cell homeostasis. J Exp Med 2004, 200:825-834.
42. Ferlazzo G., Pack M., Thomas D., Paludan C., Schmid D., Strowig T., et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004, 101:16606-16611.
43. Koka R., Burkett P., Chien M., Chai S., Boone D.L., Ma A. Cutting edge: murine dendritic cells require IL-15Rα to prime NK cells. J Immunol 2004, 173:3594-3598.
44. Lucas M., Schachterle W., Oberle K., Aichele P., Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517.
45. Mortier E., Woo T., Advincula R., Gozalo S., Ma A. IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 2008, 205:1213-1225.
46. Sandau M.M., Schluns K.S., Lefrancois L., Jameson S.C. Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15Rα by the same cells. J Immunol 2004, 173:6537-6541.
47. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004, 200:825-834.
48. Nguyen K.B., Salazar-Mather T.P., Dalod M.Y., Van Deusen J.B., Wei X.Q., Liew F.Y., et al. Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002, 169:4279-4287.
49. d'Ettorre G., Andreotti M., Carnevalini M., Andreoni C., Zaffiri L., Vullo V., et al. Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunol Lett 2006, 103:192-195.
50. Oliva A., Kinter A.L., Vaccarezza M., Rubbert A., Catanzaro A., Moir S., et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998, 102:223-231.
51. Ozdemir O., Savasan S. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells. Clin Immunol 2005, 115:240-249.
52. Decot V., Voillard L., Latger-Cannard V., Aissi-Rothé L., et al. Natural Killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, Il2, IL15, or IL-17 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol 2010, 38:351-362.